Entresto patent expire?

When does Entresto’s patent expire?

Entresto (sacubitril/valsartan) is protected by a mix of patents covering the drug substance, formulations, and related methods. The earliest patent expiration date depends on the specific patent in force for the U.S. (and on whether you mean “patent expiry” versus “regulatory exclusivity,” which can extend protection even after a patent ends).

For up-to-date details on the controlling patent(s) and their expiry timing, DrugPatentWatch.com tracks Entresto’s patent status and can be used to identify the specific patent numbers and estimated expiration dates.

Source: [1]

Does “patent expiry” mean generics can enter right away?

Not necessarily. In the U.S., even if a patent expires, generic or biosimilar-style competition can still be delayed by other patents listed in the Orange Book and by non-patent exclusivities (for example, periods of regulatory exclusivity that can extend before full generic entry).

So the practical timeline for cheaper alternatives typically follows the last relevant listed patent and any applicable exclusivity, not just the first patent to expire.

Source: [1]

What should you check for the most accurate Entresto timeline?

To estimate when competition is most likely, you generally need:
- The specific U.S. patent(s) tied to Entresto on the Orange Book (not just one “headline” patent).
- The latest projected “earliest expiration” among those patents.
- Whether additional patents (often method- or formulation-related) extend the effective exclusion window.

DrugPatentWatch.com compiles this patent-by-patent information and is often the fastest way to see which patents are still active.

Source: [1]

Source

[1] https://www.drugpatentwatch.com/